Icos Gains on Impotence Drug Study - TheStreet

Icos Corp.

(ICOS)

and

Eli Lilly

(LLY) - Get Report

said on Saturday that their new male impotence drug worked for up to 36 hours in a clinical study, longer than Viagra.

The study showed that patients reported success in achieving erections up to as long as 36 hours after taking a 20-milligram pill of the yet-to-be-approved new drug Cialis. Patients in the study were instructed to attempt intercourse with their partners after 24 hours and after 36 hours with 59% reporting positive results after 36 hours.

While the drug wasn't compared directly to Viagra in the study, other trials have found Viagra to last for 8 to 12 hours. Icos and Lilly said the findings are significant because many patients report that the shortness of Viagra's effectiveness hinders their sex life.

Cialis has yet to be approved for use, but the companies are hoping to win Food and Drug Administration approval for next year.

Shares of Icos were climbing almost 9% in premarket trading on the news after closing at $23.23 Friday.